The most recent Neuralink event featured a monkey playing Pong with its thoughts. Since then, the majority of the business’s co-founders have left, and speculations have circulated that Musk is considering investing in a competing brain chip startup. Furthermore, the fact that Neuralink has yet to get FDA regulatory permission to commence human trials shows that the firm has reached a tipping point. Whatever it has to show next month might be vital to its future, so it’s understandable that the corporation believes it needs more time to prepare.
